trending Market Intelligence /marketintelligence/en/news-insights/trending/w8lgcfE7ughRRplJKOdLLQ2 content esgSubNav
In This List

US FDA approves Anacor's eczema ointment

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


US FDA approves Anacor's eczema ointment

The U.S. FDA approved Anacor Pharmaceuticals Inc.'s Eucrisa ointment to treat mild to moderate eczema in patients two years of age and older.

The safety and efficacy of the ointment were established in two placebo-controlled trials with participants from two years of age to 79 years of age, with mild to moderate atopic dermatitis.

Participants in the trial receiving Eucrisa achieved greater response with clear or almost clear skin after 28 days of treatment.